Search

Your search keyword '"Mandarà, Marta"' showing total 25 results
Start Over Author "Mandarà, Marta"
25 results on '"Mandarà, Marta"'

4. "Defendit Numerus": A Pooled Analysis of 6145 Locally Advanced Rectal Cancer Treated with Preoperative Chemoradiotherapy.

Author

Giuliani, Jacopo, Mandarà, Marta, Muraro, Marco, Rampello, Elvira, Franceschetto, Antonella, and Fiorica, Francesco

Subjects
*SURVIVAL rate, *RECTAL cancer, *OVERALL survival, *PROGRESSION-free survival, *CANCER patients, *CHEMORADIOTHERAPY
Abstract

Objective: The optimal management of rectal cancer remains a subject of ongoing research. This meta-analysis of individual patient data assessed the benefit of chemoradiotherapy (fluorouracil-based) in local advanced rectal cancer: disease-free survival and overall survival. Methods: We pooled the data of 6145 patients from 24 studies of rectal cancer who received neoadjuvant radiotherapy with concomitant fluorouracil or capecitabine and surgery. The PRISMA 2020 abstract checklist was followed. Individual participant survival was reconstructed with an algorithm from published Kaplan–Meier curves. Results: The median OS was not reached; the mean survival time was 135.4 months (127.9–141.5). The median DFS was 176.9 months, and the mean disease-free survival time was 122.6 months (111.7–131.9). Conclusions: We provided a benchmark for future studies on rectal cancer treatment. The present results can be used in decision-making for locally advanced rectal cancer patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Why intensify the neo-adjuvant approach with chemotherapy and radiotherapy in rectal cancer? A Systematic review and meta-analysis

Author

Tebano, Umberto, primary, Mandarà, Marta, additional, Giuliani, Jacopo, additional, Franceschetto, Antonella, additional, Giorgi, Carlotta, additional, Missiroli, Sonia, additional, Gabbani, Milena, additional, Zaninelli, Marta, additional, Napoli, Giuseppe, additional, Luca, Nicoletta, additional, Mangiola, Daniela, additional, Muraro, Marco, additional, Visentin, Sebastiano, additional, Perrone, Maria Sole, additional, Pinton, Paolo, additional, and Fiorica, Francesco, additional

Published
2023
Full Text
View/download PDF

11. Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab

Author

Pasello, Giulia, primary, Lorenzi, Martina, additional, Calvetti, Lorenzo, additional, Oliani, Cristina, additional, Pavan, Alberto, additional, Favaretto, Adolfo, additional, Palazzolo, Giovanni, additional, Giovanis, Petros, additional, Zustovich, Fable, additional, Bonetti, Andrea, additional, Bernardi, Daniele, additional, Mandarà, Marta, additional, Aprile, Giuseppe, additional, Crivellaro, Giovanna, additional, Sinigaglia, Giusy, additional, Tognazzo, Sandro, additional, Morandi, Paolo, additional, Bortolami, Alberto, additional, Marino, Valentina, additional, Bonanno, Laura, additional, Guarneri, Valentina, additional, and Conte, PierFranco, additional

Published
2022
Full Text
View/download PDF

12. Lobular Breast Cancer Conspicuity on Digital Breast Tomosynthesis Compared to Synthesized 2D Mammography: A Multireader Study

Author

Romanucci, Giovanna, primary, Zantedeschi, Lisa, additional, Ventriglia, Anna, additional, Mercogliano, Sara, additional, Bisighin, Maria Vittoria, additional, Cugola, Loredana, additional, Bricolo, Paola, additional, Rella, Rossella, additional, Mandarà, Marta, additional, Benassuti, Chiara, additional, Caneva, Andrea, additional, and Fornasa, Francesca, additional

Published
2021
Full Text
View/download PDF

13. Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study

Author

Guarneri, Valentina, Bassan, Franco, Zagonel, Vittorina, Milella, Michele, Zaninelli, Marta, Cattelan, Anna Maria, Vianello, Andrea, Gori, Stefania, Aprile, Giuseppe, Azzarello, Giuseppe, Chiari, Rita, Favaretto, Adolfo, Oliani, Cristina, Scola, Annamaria, Pastorelli, Davide, Mandarà, Marta, Zustovich, Fable, Bernardi, Daniele, Chiarion-Sileni, Vanna, Morandi, Paolo, Toso, Silvia, Di Liso, Elisabetta, Ziampiri, Stamatia, Caccese, Mario, Zampiva, Ilaria, Puccetti, Oliviero, Celestino, Michele, Dieci, Maria Vittoria, and Conte, PierFranco

Subjects
Adult, Male, Cancer Research, COOVID19, Community Networks, Severity of Illness Index, Chemotherapy, COVID-19, Mortality, Patients with cancer, SARS-CoV-2 infection, Aged, Aged, 80 and over, Disease Progression, Female, Hospital Mortality, Hospitalization, Humans, Intensive Care Units, Italy, Middle Aged, Neoplasms, Pandemics, Prognosis, Registries, SARS-CoV-2, 80 and over, Original Research, Cancer Patients, Oncology
Abstract

Introduction COVID-19 pandemic started in Italy with clusters identified in Northern Italy. The Veneto Oncology Network ROV licensed dedicated guidelines to ensure proper care minimizing the risk of infection in cancer patient. ROVID is a regional registry aimed at describing epidemiology and clinical course of SARS-CoV-2 infection in cancer patients. Materials and methods Patients with cancer diagnosis and documented SARS-CoV-2 infection are eligible. Data on cancer diagnosis, comorbidities, anticancer treatments as well as details on SARS-CoV-infection (hospitalization, treatments, fate of the infection) have been recorded. Logistic regression analysis was applied to calculate the association between clinical/laboratory variables and death from any cause. Results 170 patients have been enrolled. Median age at time of the SARS-CoV-infection was 70 years (25-92). The most common cancer type was breast cancer (n=40). The majority of the patients had stage IV disease. Half of the patients had 2 or more comorbidities. The majority of the patients (78%) presented with COVID-19 symptoms. More than 77% of the patients were hospitalized, and 6% were admitted to intensive care units. Overall, 104 patients have documented resolution of the infection. Fifty-seven patients (33%) have died. In 29 cases (17%) the cause of death was directly correlated to SARS-CoV-2 infection. Factors significantly correlated with the risk of death were: ECOG PS, age, presence of 2 or more comorbidities, presence of dyspnea, COVID-19 phenotype >=3, hospitalization, intensive care unit admission, neutrophils/lymphocytes ratio and thrombocytopenia. Conclusions The mortality rate reported in this confirms the frailty of this population. These data reinforce the need to protect cancer patients from SARS-CoV2 infection., Highlights • Cancer patients represent a vulnerable population, with risk of severe complications. • Active anticancer therapy does not increase the risk of death. • The risk of death can be stratified according to clinical and laboratory parameters. • Cancer services must adopt all preventive measures to protect patients from infection.

Published
2021

14. Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study

Author

Guarneri, Valentina, primary, Bassan, Franco, additional, Zagonel, Vittorina, additional, Milella, Michele, additional, Zaninelli, Marta, additional, Cattelan, Anna Maria, additional, Vianello, Andrea, additional, Gori, Stefania, additional, Aprile, Giuseppe, additional, Azzarello, Giuseppe, additional, Chiari, Rita, additional, Favaretto, Adolfo, additional, Oliani, Cristina, additional, Scola, Annamaria, additional, Pastorelli, Davide, additional, Mandarà, Marta, additional, Zustovich, Fable, additional, Bernardi, Daniele, additional, Chiarion-Sileni, Vanna, additional, Morandi, Paolo, additional, Toso, Silvia, additional, Di Liso, Elisabetta, additional, Ziampiri, Stamatia, additional, Caccese, Mario, additional, Zampiva, Ilaria, additional, Puccetti, Oliviero, additional, Celestino, Michele, additional, Dieci, Maria Vittoria, additional, and Conte, PierFranco, additional

Published
2021
Full Text
View/download PDF

15. Psychological impact of Covid-19 pandemic on oncological patients: A survey in Northern Italy

Author

Pigozzi, Eva, primary, Tregnago, Daniela, additional, Costa, Lucia, additional, Insolda, Jessica, additional, Turati, Enrico, additional, Rimondini, Michela, additional, Donisi, Valeria, additional, Madera, Pietro, additional, Fiorica, Francesco, additional, Giuliani, Jacopo, additional, Greco, Filippo, additional, Mercanti, Anna, additional, Trolese, Annarita, additional, Furlani, Lara, additional, Piacentini, Paolo, additional, Durante, Emilia, additional, Mandarà, Marta, additional, Pilotto, Sara, additional, Avancini, Alice, additional, Trestini, Ilaria, additional, Zaninelli, Marta, additional, Moretti, Francesca, additional, Milella, Michele, additional, and Bonetti, Andrea, additional

Published
2021
Full Text
View/download PDF

23. Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy.

Author

Pellini, Francesca, Granuzzo, Eleonora, Urbani, Silvia, Mirandola, Sara, Caldana, Marina, Lombardi, Davide, Fiorio, Elena, Mandarà, Marta, and Pollini, Giovanni Paolo

Subjects
CELL receptors, HEALTH care teams, MASTECTOMY, MEDICAL records, SCIENTIFIC observation, PUBLIC health surveillance, RARE diseases, TUMOR classification, BRCA genes, RETROSPECTIVE studies, FAMILY history (Medicine), ELECTRONIC health records, MALE breast cancer, ACQUISITION of data methodology, DISEASE risk factors
Abstract

Background: Male breast cancer (MBC) is a rare disease with a rising incidence trend. The major risk factors related to MBC are a positive family history of breast cancer (BC) and BRCA1/2 mutations, which indicate a relevant genetic role. Methods: In this retrospective series, we enrolled 69 male patients presenting with male breast cancer (MBC) between 01/01/1992 and 31/12/2018, and 26 high-risk not-affected men presenting between 01/01/2016 and 31/12/2018. Participants' electronic clinical records were reviewed. Patients' data reported age at diagnosis, tumor characteristics, therapeutic management, and BRCA1/2 status as well as a family history of breast, ovarian, or prostate cancer (PCa) in first-degree relatives. Results: We analyzed 69 MBC patients. Median age was 64 years. The majority of tumors diagnosed were of an early TNM stage. The most frequent histological subtype was invasive ductal carcinoma (76.7%). Hormone receptors were positive in >90% of MBC cases. Nearly all patients underwent modified radical mastectomy or total mastectomy. Adjuvant endocrine therapy was delivered in 59.4%. Among MBC-affected patients, we recorded a high percentage of a positive family history of BC. Mutational analysis for the BRCA1/2 genes was performed in 17 MBC patients; 11.8% were carriers of BRCA2 pathogenic mutations. Among 26 healthy high-risk subjects included in this case series, 4 were BRCA1 mutation carriers and 9 were BRCA2 mutation carriers. Discussion: We evaluated the distribution of clinicopathological characteristics in MBC subjects and assessed the frequency of mutations in the BRCA genes in affected patients and healthy high-risk subjects, with the aim of proposing a surveillance program for BC and PCa. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

24. Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes

Author

Giotta, Francesco, primary, Acito, Luigi, additional, Candeloro, Giampiero, additional, Del Medico, Pietro, additional, Gadaleta‐Caldarola, Gennaro, additional, Giordano, Guido, additional, Gueli, Rossana, additional, Lugini, Antonio, additional, Magri, Valentina, additional, Mandarà, Marta, additional, Masci, Giovanna, additional, Pisconti, Salvatore, additional, Pistelli, Mirco, additional, Rizzi, Anna, additional, Salesi, Nello, additional, Schirone, Alessio, additional, Scognamiglio, Giovanni, additional, Tedeschi, Maria, additional, and Zucchinelli, Patrizia, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results